{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T17:25:50Z","timestamp":1769707550771,"version":"3.49.0"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>RET fusions are rare, and occur in 1%-2% of all non-small cell lung cancer (NSCLC) patients. While neoadjuvant immunotherapy-chemotherapy has demonstrated significant benefit for resectable NSCLC, data remain limited for oncogene-positive NSCLC, particularly for rare alterations like RET fusions. Herein, we present a clinical case of a patient with stage IIIA RET fusion-positive adenocarcinoma who received neoadjuvant nivolumab immunotherapy combined with nab-paclitaxel and carboplatin chemotherapy followed by surgery. The postoperative pathologic results revealed pathological complete response (pCR) and no residual viable tumor cells were observed in lymph nodes. This case validates the clinical activity of immunotherapy-chemotherapy in the neoadjuvant setting, providing a foundation for continued exploration in the treatment of early-stage RET fusion-positive NSCLC.<\/jats:p>","DOI":"10.3389\/fonc.2026.1730615","type":"journal-article","created":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:22:38Z","timestamp":1769664158000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Complete pathologic response to neoadjuvant immunotherapy-chemotherapy in a patient with RET fusion-positive non-small cell lung cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenlei","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengxiang","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Songwen","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-346","article-title":"Decade in review: a new era for RET-rearranged lung cancers","volume":"9","author":"Choudhury","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"B2","doi-asserted-by":"publisher","first-page":"4146","DOI":"10.3390\/cancers15164146","article-title":"RET-altered cancers\u2014A tumor-agnostic review of biology, diagnosis and targeted therapy activity","volume":"15","author":"Desilets","year":"2023","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.992636","article-title":"Precision oncology for RET-related tumors","volume":"12","author":"Verrienti","year":"2022","journal-title":"Front Oncol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"101911","DOI":"10.1016\/j.ctrv.2019.101911","article-title":"RET fusions in solid tumors","volume":"81","author":"Li","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyac264","article-title":"RET fusion-positive non-small cell lung cancer: the evolving treatment landscape","volume":"28","author":"Novello","year":"2023","journal-title":"Oncologist"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00393","article-title":"Selpercatinib in patients with RET fusion-positive non-small-cell lung cancer: updated safety and efficacy from the registrational LIBRETTO-001 phase I\/II trial","volume":"41","author":"Drilon","year":"2023","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309457","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion\u2013positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"108083","DOI":"10.1016\/j.lungcan.2025.108083","article-title":"Rearranged during transfection (RET) lung cancer \u2013 Update on targeted therapies","volume":"200","author":"Mullally","year":"2025","journal-title":"Lung Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2202170","article-title":"Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer","volume":"386","author":"Forde","year":"2022","journal-title":"N Engl J Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"104080","DOI":"10.1016\/j.critrevonc.2023.104080","article-title":"Neoadjuvant therapy in non-small cell lung cancer","volume":"190","author":"Grant","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.atssr.2022.11.014","article-title":"Neoadjuvant targeted therapy in non\u2013small cell lung cancer and its impact on surgical outcomes","volume":"1","author":"Sorin","year":"2023","journal-title":"Ann Thorac Surg Short Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-3766.2018.02.010","article-title":"A randomized controlled study of erlotinib versus pemetrexed combined with cisplatin in neoadjuvant therapy of stage IIIA EGFR-mutant lung adenocarcinoma","volume":"40","author":"Chen","year":"2018","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00075","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non&x2013;Small-cell lung cancer (EMERGING-CTONG 1103): A randomized phase II study","volume":"37","author":"Zhong","year":"2019","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41392-022-01286-3","article-title":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised phase II trial","volume":"8","author":"Zhong","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12957-024-03434-1","article-title":"Neoadjuvant PD-(L)1 blockade plus platinum-based chemotherapy for potentially resectable oncogene-positive non-small cell lung cancer","volume":"22","author":"Zhang","year":"2024","journal-title":"World J Surg Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30453-8","article-title":"Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial","volume":"21","author":"Provencio","year":"2020","journal-title":"Lancet Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.1115","article-title":"Neoadjuvant PD-1 and PD-L1 blockade with chemotherapy for borderline resectable and unresectable stage III non\u2013small cell lung cancer","volume":"11","author":"Ricciuti","year":"2025","journal-title":"JAMA Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz167","article-title":"Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry","volume":"30","author":"Mazieres","year":"2019","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/PO.18.00386","article-title":"Immunophenotype and response to immunotherapy of RET-rearranged lung cancers","volume":"3","author":"Offin","year":"2019","journal-title":"JCO Precis Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-19-0056","article-title":"ALK and RET inhibitors promote HLA class I antigen presentation and unmask new antigens within the tumor immunopeptidome","volume":"7","author":"Oh","year":"2019","journal-title":"Cancer Immunol Res"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1730615\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T05:22:42Z","timestamp":1769664162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1730615\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":22,"alternative-id":["10.3389\/fonc.2026.1730615"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1730615","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,29]]},"article-number":"1730615"}}